Enhancement of Facial Rejuvenation Through a Combination of 1565 nm Non-Ablative Fractional Laser with 30% Supramolecular Salicylic Acid
September 27th, 2024
The purpose of this project is to effectively reduce the occurrence of adverse reactions such as erythema and pigmentation after non-ablative fractional laser treatment by combining 1565 non-ablative fractional laser with 30% super molecular salicylic acid, providing patients with a safer new method of facial rejuvenation treatment.
My research focuses on facial rejuvenation, and I want to translate cleaning experience into evidence-based medical results through cleaning trials. Currently, several clinicians have implemented the use of 30%supramolecular salicylic acid, immediately following 1, 565 nanometer non-ablative fractional laser treatment. Discovering that this combined approach outperforms the sole application of 1, 565 nanometer non-ablative fractional laser, our research validates this finding and further demonstrates that the distinct advantage of this combined therapy nicely its effectiveness in resolving pigmented and reddened areas.
Our method can reduce the incidence of post laser pigmentation and expedite feeding post laser arrhythmia. Moreover, the combined treatment also reduces the number of hospital visits for patients. To begin, clean the selected patient's face with a cleanser, and using a skin detector, perform the skin test.
Apply the compound lidocaine cream externally to the treatment area. After 40 minutes, wash the entire face with water and dry it with sterile gauze. Next, choose the reser effects mode on the 1, 565 nanometer non-ablative fractional laser device for the treatment.
In the energy setting key, set the energy level between 30 and 40 millijoules, and adjust the density setting between 200 and 300 spots per square centimeter. Then, have the patient lie comfortably on the treatment bed with the doctor sitting at the head end of the bed. Wipe the entire treatment area on the patient's face with iota four.
After removing the iodine with sterile saline, dry the area with sterile gauze. With a 75%alcohol pad, disinfect the treatment head of the device. Next, cover the patient's eyes with an eye mask.
Choose the appropriate spot size and shape on the device interface and click ready. Gently place the treatment head on the patient's skin surface and press the trigger button. Release the trigger button after the treatment prompt sound stops.
Lift the handle and proceed to the next spot for the treatment, taking all the precautions. Once the face is treated, click standby on the instrument treatment interface and immediately apply 30%supramolecular salicylic acid to the entire face. Wearing latex gloves, gently massage the face in a circular motion with fingers to promote absorption.
Rinse the face with physiological saline immediately when the endpoint reaction appears, or within 10 minutes of application. For post-treatment care, apply cold saline gauze to the patient's face for 30 minutes, followed by moisturizing and repairing products. A significant improvement in facial pores and wrinkles was observed in laser alone therapy, as well as the combined therapy with salicylic acid treatment.
However, a more effective reduction in redness was evident after the combined therapy by day 30. The clinical scoring for female facial aging also indicated significant benefits from both the treatments with the combination therapy achieving better outcomes than the laser alone.
Overview
This study investigates a novel approach to facial rejuvenation by combining 1565 nm non-ablative fractional laser treatment with 30% supramolecular salicylic acid. The goal is to minimize adverse reactions such as erythema and pigmentation, providing a safer treatment option for patients.
Key Study Components
Area of Science
- Dermatology
- Cosmetic procedures
- Laser therapy
Background
- Facial rejuvenation techniques are evolving to enhance patient safety.
- Adverse reactions from laser treatments can significantly impact patient satisfaction.
- Supramolecular salicylic acid has shown promise in improving treatment outcomes.
- Combining therapies may offer synergistic benefits.
Purpose of Study
- To reduce the occurrence of post-laser pigmentation and erythema.
- To validate the effectiveness of combined laser and salicylic acid treatments.
- To improve patient recovery and reduce hospital visits.
Methods Used
- Application of 1565 nm non-ablative fractional laser treatment.
- Immediate application of 30% supramolecular salicylic acid post-laser.
- Skin testing using a skin detector prior to treatment.
- Monitoring patient outcomes and adverse reactions.
Main Results
- The combined treatment significantly outperformed the laser treatment alone.
- Reduced incidence of post-laser erythema and pigmentation was observed.
- Patients experienced expedited recovery times.
- Fewer hospital visits were required for patients undergoing the combined treatment.
Conclusions
- The combination of 1565 nm laser and supramolecular salicylic acid is effective in facial rejuvenation.
- This approach enhances patient safety and satisfaction.
- Further studies may solidify these findings and expand treatment applications.
Frequently Asked Questions
Executive Industry Relevance
Combining 1565 nm non-ablative fractional laser with 30% supramolecular salicylic acid addresses a key challenge in dermatological device-based rejuvenation: minimizing post-procedural inflammation and pigmentation. This dual-modality approach enhances predictive confidence in treatment outcomes and supports risk-adjusted advancement of new dermatological protocols. The method's ability to reduce adverse events and hospital visits is directly relevant for translational research and portfolio differentiation in aesthetic therapeutics.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables quantitative assessment of inflammation and pigmentation endpoints post-intervention.
- Supports mechanistic de-risking by isolating the effects of combined laser and chemical modalities.
- Facilitates functional validation of anti-inflammatory and regenerative pathways in skin models.
Screening & Assay Development
- Provides a reproducible protocol for evaluating skin recovery and adverse event profiles.
- Standardizes measurement of erythema and pigmentation as quantitative dependent variables.
- Enables downstream screening of adjunctive compounds or device parameters for synergistic effects.
Translational & Preclinical Research
- Aligns with disease-relevant models of skin aging and post-inflammatory pigmentation.
- Supports continuity from device-based discovery to preclinical validation of combination therapies.
- Informs risk-adjusted decisions for advancing new dermatological interventions.
Pipeline & Workflow Integration
This method integrates into the dermatology discovery continuum from early mechanistic studies through preclinical validation of device-chemical combinations.
- Discovery Biology: Enables hypothesis testing on inflammation and pigmentation mechanisms following device intervention.
- Screening: Provides standardized, reproducible endpoints for erythema and pigmentation reduction.
- Analytics: Delivers quantitative readouts for comparing single versus combination treatments.
- Translational Research: Bridges discovery findings to preclinical models of skin rejuvenation and repair.
- Enterprise Reuse: Establishes a protocol adaptable to other device-chemical combination studies in dermatology.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in anti-inflammatory and anti-pigmentation outcomes.
- Operational Value: Improves standardization and reproducibility of dermatological intervention protocols.
- Strategic Value: Enables better go/no-go decisions for advancing combination therapies in the pipeline.
- Portfolio Impact: Supports risk-adjusted prioritization of device-chemical combinations for clinical translation.
Implementation Considerations
- Requires expertise in dermatological device operation and chemical application.
- Needs access to validated skin assessment tools and quantitative analytics.
- Demands cross-team standardization of endpoint measurement and reporting.
- Adaptation may be needed for different skin types or aging models.
- Short-term erythema and pigmentation must be monitored as practical limitations.
